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Escherichia coli strains producing Shiga-like toxin II variant (SLT-IIe, formerly called SLT-IIv) cause edema
disease in weaned pigs. Vaccination of pigs with a genetically modified form of Shiga-like toxin IIe, SLT-
IIe(E167Q), has been previously shown to be nontoxic and to induce antibodies to SLT-IIe (V. M. Gordon, S.
C. Whipp, H. W. Moon, A. D. O’Brien, and J. E. Samuel, Infect. Immun. 60:485–502, 1992). Fifty micrograms
of SLT-IIe(E167Q) toxin was used to vaccinate suckling pigs at 1 and 2 weeks of age. Both vaccinated and
nonvaccinated pigs were orally inoculated with an SLT-IIe-producing strain of E. coli after weaning (3 to 4
weeks of age). Pigs fed a low-protein diet that were not vaccinated with SLT-IIe(E167Q) developed subclinical
edema disease, histologically evident as vascular necrosis. Pigs fed a high-protein diet that were not vaccinated
with SLT-IIe(E167Q) developed clinical edema disease manifested as vascular necrosis, reduced weight gain,
ataxia, palpebral edema, lateral recumbency, and death. Pigs vaccinated with SLT-IIe(E167Q) had a reduction
in the incidence of subclinical edema disease and never developed clinical edema disease. These data demon-
strate that vaccination with a genetically modified form of SLT-IIe prevents edema disease and are consistent
with the notion that diet influences susceptibility to edema disease.
Escherichia coli strains producing one or more cytotoxins in
the family of Shiga-like toxins (SLTs) have been implicated as
the cause of hemorrhagic colitis and hemolytic-uremic syn-
drome in humans (17–20, 29, 33), diarrhea in calves (7, 25, 34),
and edema disease in swine (8, 10, 26, 35). These toxins are
bipartite toxins consisting of five B subunits responsible for
binding to specific cell receptors and an A subunit containing
the enzymatic activity (28). The activity of the A subunit in-
hibits protein synthesis, resulting in cytotoxicity and the clinical
syndromes cited above (9, 14, 30). The specificity of the clinical
syndromes attributable to the different SLTs is thought to be a
function of differing receptor specificities (31).
The clinical manifestations of edema disease include palpe-
bral edema and neurologic dysfunction manifested as ataxia,
lateral recumbency, and death (27, 37). These signs result from
microangiopathy and vascular necrosis caused by a variant of
Shiga-like toxin II (SLT-IIe, formerly called SLT-IIv) (10, 23,
26). Subclinical edema disease is characterized by microangi-
opathy in animals that do not manifest the signs cited above
and has been observed to occur in experimentally infected
animals (22). Diet and other factors influence the susceptibility
of pigs to E. coli producing SLT-IIe (27) and could determine
whether subclinical or clinical edema disease occurs following
infection.
There are several lines of evidence that antitoxic immunity
protects against diseases caused by E. coli producing Shiga-like
toxins. In 1955, Howard observed that shigella dysentery anti-
toxin could protect mice and rabbits against lethal injections of
Shiga toxin (13). More recently, similar protection was
achieved in mice which had received a monoclonal antibody
specific for Shiga toxin (16). Passive protection of mice exper-
imentally infected with SLT-II-producing E. coli was also dem-
onstrated with anti-SLT-II monoclonal antibody (38). Awad-
Masalmeh et al. (1, 2) vaccinated pigs with a toxoid prepared
by exposure of crude SLT-IIe to glutaraldehyde and reported
protection against naturally occurring and experimentally in-
duced edema disease. MacLeod and Gyles (24) subsequently
inactivated purified SLT-IIe by exposure to glutaraldehyde and
demonstrated that passive transfer of antibodies against, or
intramuscular vaccination of 2-week-old pigs with, this product
protected pigs against a lethal intravenous dose of SLT-IIe.
Previously, a toxoid prepared by chemically modifying SLT-
IIe with 1% formaldehyde was tested for efficacy against sub-
clinical edema disease (11). Even though this preparation had
no detectable cytotoxic activity in Vero cells, pigs vaccinated
with this SLT-IIe toxoid had a reduced rate of gain in com-
parison with littermate controls (11). Since the presence of
glutamate at position 167 of the mature A subunit of SLTs was
implicated as being important for enzymatic activity with both
SLT-I and SLT-II (12), SLT-IIe toxin was modified by site-
directed mutagenesis and tested as a potential vaccine to pre-
vent edema disease (11). This genetically modified SLT-IIe
toxin differed from the parent toxin with respect to one amino
acid: the glutamate at position 167 was changed to glutamine
(E167Q). The cytotoxic activity and lethality to mice of SLT-
IIe(E167Q) were reduced 106- and 104-fold, respectively, in
comparison with those of the native toxin. Moreover, vaccina-
tion of pigs with SLT-IIe(E167Q) did not have deleterious
effects on rate of gain (11).
The primary objective of the present study was to determine
if vaccination of pigs with SLT-IIe(E167Q) could prevent both
subclinical and clinical edema disease. Initially, SLT-IIe(E16
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7Q) was tested by using a previously described subclinical
edema disease model (22). This model was modified, and clin-
ical edema disease resulted when the protein content of the
diet was increased. SLT-IIe(E167Q) was also tested in this
experimental model of clinical edema disease. These experi-
ments demonstrated that vaccination with SLT-IIe(E167Q)
markedly reduced the incidence of both subclinical and clinical
edema disease.
MATERIALS AND METHODS
Bacterial strains. E. coli S1191 (serogroup O139), originally isolated from a
pig with clinical edema disease, and 123 (serogroup O43), originally isolated
from a clinically normal pig, were used in principals and controls, respectively.
Strain S1191 is hemolytic and produces SLT-IIe, heat-stable enterotoxin b, and
the F107 fimbriae which mediate colonization of the swine intestine (3, 15).
Strain 123 is nonhemolytic, nontoxigenic, and nonpathogenic.
Mutant toxin vaccine. The mutant toxin SLT-IIe(E167Q) was produced by
site-directed mutagenesis to replace glutamate at position 167 with glutamine to
reduce the enzymatic activity of the A subunit, as previously described (11).
Animal experiments. Three different experimental models were used to de-
termine if diet and inoculation method affected severity of edema disease. In all
three models, swine were vaccinated with the modified SLT-IIe(E167Q) protein
to determine the ability to induce protective immunity against an edema disease-
causing strain of E. coli.
Model A. Model A has been previously used to induce subclinical edema
disease (11). One hundred and two naturally farrowed piglets from 12 crossbred
litters were randomly assigned to four groups. Two sham-vaccinated groups were
injected subcutaneously with 1 ml of A1(OH)3 adjuvant-phosphate-buffered sa-
line (1:1), and the two vaccinated groups were injected subcutaneously with 1 ml
of adjuvant containing 50 mg of SLT-IIe(E167Q). Pigs were vaccinated at 7 and
14 days of age and weaned at 3 weeks of age, and fasted on the night of weaning.
Following the overnight fast, pigs were inoculated once intragastrically with 1010
CFU of E. coli and then fed a commercial ration containing 18.0% crude protein
ad libitum. Nonvaccinated (n 5 26) and vaccinated (n 5 26) principals were
inoculated with edema disease-causing E. coli S1191. Nonvaccinated (n 5 25)
and vaccinated (n 5 25) controls were inoculated with the nonpathogenic E. coli
123.
Model B. Because model A demonstrated that vaccinated and unvaccinated
controls challenged with strain 123 behaved similarly, only one group of controls
was used in models B and C. Thirty-four pigs from five crossbred litters were
randomly assigned to three groups. Pigs were weaned at 3 weeks of age and fed
a commercial ration which contained 17.0% crude protein ad libitum. Vacci-
nated principals (n 5 11) were inoculated per os at 4, 6, 8, and 10 days post-
weaning with gelatin capsules containing approximately 1 g of feed and 1010 CFU
of strain S1191. The control group (n 5 11) was similarly inoculated with strain
123. Nonvaccinated principals (n 5 12) were similarly inoculated with strain
S1191. Feed consumption was monitored daily.
Model C. Thirty-six pigs from six litters were randomly assigned to three
groups and vaccinated and inoculated as in model B. All pigs in the model were
fed a commercial ration containing 21.0% crude protein ad libitum. The vacci-
nated (n 5 8) and unvaccinated (n 5 17) principals were inoculated with edema
disease strain S1191 four times, as in model B. Eleven control pigs were similarly
challenged four times with the nonpathogenic strain 123. Feed consumption was
monitored daily.
Clinical observations, postmortem, and serology. All pigs were weighed daily
and observed for clinical signs of edema disease (palpebral edema, ataxia, lateral
recumbency, or death). Any animal in lateral recumbency or exhibiting ataxia for
48 h was euthanized. Pigs were necropsied between 12 and 17 days after the
initial challenge. Spiral colon, ileum, and brain stem specimens were collected
and immersed in neutrally buffered 10% formalin. Histologic sections were
prepared as described previously (22), stained with hematoxylin and eosin,
coded, and then examined by light microscopy. The histologic sections were
examined in a double-blind fashion. Animals were designated positive for vas-
cular necrosis if one or more of the tissues examined had at least two vessels with
vascular necrosis. All animals were bled at the time of the first challenge and at
necropsy. Serum antibodies against SLT-IIe were determined by serum neutral-
ization of SLT-IIe Vero cell cytotoxicity as described previously (11).
Statistical analysis. The rates of gain of the various treatment groups after
challenge were compared by using one-way analysis of variance (32) and were
calculated from linear regression for individual pigs in each treatment group.
Weight gain of pigs euthanized or found dead early in the experiment was not
included. The ratio of daily feed consumption/weight gain was determined only
for models B and C and was calculated by dividing daily feed consumption
(kilograms) of a treatment group by daily weight gain (kilograms) of all pigs in
that treatment group. The ratios of average daily feed consumption/weight gain
for treatment groups were compared by one-way analysis of variance (32).
RESULTS
Model A. All model A pigs were inoculated once with either
the nonpathogenic strain 123 (controls) or the edema disease-
causing strain S1191 (principals). No clinical signs of edema
disease were observed in any pig (Table 1). However, microan-
giopathy consistent with edema disease was observed in 9 of 26
nonvaccinated principals. Such histologic lesions were ob-
served in only 2 of 26 vaccinated principals. No such lesions
were observed in 25 nonvaccinated or 25 vaccinated controls.
Nonvaccinated principals had a slight, but not significant (P
5 0.09), decreased rate of gain relative to those of the other
three treatment groups (Fig. 1). Thirty-five of 49 pigs vacci-
nated with SLT-IIe(E167Q) and 0 of 51 nonvaccinated pigs
developed toxin-neutralizing serum antibody titers greater
than 1:4 prior to challenge. Titers of antibody to SLT-IIe in
serum increased after challenge in vaccinated pigs inoculated
with strain 123 as well as in those inoculated with strain S1191
(Table 2).
Model B. Model B animals were challenged four times with
either nonpathogenic strain 123 (controls) or edema disease
strain S1191 (principals) to determine if multiple inoculations
could induce clinical edema disease. No clinical signs of edema
disease were observed in any pig (Table 1). Watery diarrhea
was noted 6 to 11 days postweaning in all vaccinated and
nonvaccinated principals but not in controls. Microangiopathy
consistent with edema disease was noted in 6 of 12 nonvacci-
nated principals. No such lesions were observed in the 11
controls or the 11 vaccinated principals.
The nonvaccinated principals had a slight, but not significant
(P5 0.18), decreased rate of gain relative to those of the other
two groups (Fig. 2). The ratios of average daily feed consump-
tion/weight gain of the three treatment groups were not sig-
nificantly different. Animals vaccinated with SLT-IIe(E167Q)
developed a median serum antibody titer of 1:16, which likely
conferred the protection from subclinical edema disease (Ta-
ble 2).
Model C. Multiple inoculations with edema disease strain
S1191 increased the incidence of subclinical edema disease in
model B animals relative to model A animals; however, no
animals developed clinical edema disease. Therefore, an addi-
tional modification was made to enhance the ability to gener-
ate clinical edema disease in model C. Animals were fed a
high-protein diet (comparable to commonly used commercial
weaning rations) and inoculated four times with either non-
pathogenic strain 123 (controls) or edema disease strain S1191
(principals). Clinical signs of edema disease were observed to
be present in 10 of the 17 nonvaccinated principals (Table 1).
Four pigs in this group developed clinical signs of edema dis-
ease (rear-leg ataxia and/or palpebral edema) and recovered.
Six pigs in this group developed clinical signs of edema disease
and did not recover. One died of edema disease, three were in
lateral recumbency and were euthanized, and two were ill
(rear-leg ataxia) for 2 days and were euthanized. Sixteen of the
TABLE 1. Effect of diet and number of inoculations on prevalence
of clinical edema disease
Model Diet (% protein) No. of inoculations No. with clinical edemadiseasea
A 18 1 0/26
B 17 4 0/12
C 21 4 10/17
a Number of nonvaccinated principals with clinical edema disease/total num-
ber of nonvaccinated principals. No clinical edema disease was observed in any
of the controls or vaccinated principals.
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17 pigs in this group had microangiopathy consistent with
edema disease. No clinical signs of edema disease or vascular
necrosis were observed in the 11 controls or in the 8 vaccinated
principals.
Watery diarrhea was noted 5 to 9 days postweaning in all
nonvaccinated and vaccinated principals but not in the con-
trols. Vaccinated pigs had a median serum antibody titer of
1:16 following vaccination, and this likely conferred protection
against clinical edema disease (Table 2). Antibody titers in-
creased following inoculation with either strain 123 or strain
S1191. Nonvaccinated principals had a significantly lower rate
of gain relative to those of the other two treatment groups (Fig.
3) (P, 0.001). Nonvaccinated principals had a ratio of average
daily feed consumption/weight gain (6 standard deviation) of
2.44 (6 1.72), which was significantly different from results for
the other two groups (P , 0.05). The ratios of average daily
feed consumption/weight gain were 1.34 (6 0.53) for controls
and 1.42 (6 0.56) for vaccinated principals.
DISCUSSION
Vaccination of suckling piglets with the mutant toxin SLT-
IIe(E167Q) subsequent to challenge with edema disease strain
S1191 markedly decreased the incidence of vascular lesions in
all three models. This was consistent with the evidence indi-
cating that such lesions are caused by SLT-IIe (4, 11). The
results obtained with model A confirm a previous report that a
single inoculation of weaned pigs with E. coli S1191 results in
subclinical edema disease manifested as vascular necrosis.
However, vascular necrosis occurred less frequently in model
A in this study (9 of 26 nonvaccinated principals) than reported
previously (20 of 21 pigs) (22). Increasing the number of inoc-
ulations with strain S1191 to 4 in model B versus 1 in model A
slightly increased the incidence of vascular necrosis (6 of 11
versus 9 of 26 nonvaccinated principals), but no clinical edema
disease was observed. Clinical edema disease was only seen in
model C in 10 of 17 unvaccinated principals challenged four
times with strain S1191 and fed a high-protein diet. All but 1 of
the 17 pigs in this group developed vascular necrosis.
Model C was the best model for studying vaccine efficacy, as
only in this model did nonvaccinated principals develop clinical
edema disease. Also, vascular necrosis was much more fre-
quent than in models A and B. However, models A and B were
useful for studying vaccine efficacy against a mild, subclinical
form of edema disease. Vaccination of suckling piglets with
SLT-IIe(E167Q) prevented both clinical edema disease and
FIG. 1. Effect of vaccination with SLT-IIe(E167Q) and subclinical edema disease on rate of gain in pigs fed an 18% protein diet and inoculated one time. Pigs were
either vaccinated with 50 mg of mutant toxin or not vaccinated at 1 and 2 weeks of age. Vaccinated (n 5 26) and nonvaccinated (n 5 26) principals were inoculated
intragastrically 1 day postweaning with 1010 CFU of strain S1191. Vaccinated (n 5 25) and nonvaccinated (n 5 25) controls were similarly inoculated with strain 123.
S.E., standard error.
TABLE 2. Anti-SLT-IIe titers in vaccinated and nonvaccinated pigs
Model Group
Anti-SLT-IIe titera
Prevacci-
nation
Prechal-
lenge
Postchal-
lenge
A Nonvaccinated controls 0 0 0
Vaccinated controls 0 32 128
Nonvaccinated principals 0 0 0
Vaccinated principals 0 32 128
B Nonvaccinated principals 0 0 0
Vaccinated principals 0 16 32
Vaccinated controls 0 16 16
C Nonvaccinated principals NDb 0 0
Vaccinated principals ND 16 64
Vaccinated controls ND 16 64
aMedian titer for each group expressed as the minimum dilution that neu-
tralized at least 50% of the cytotoxic activity of 10 Vero 50% cytotoxic dose units
of SLT-IIe.
b ND, not determined.
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subclinical edema disease in model C. Moreover, the enzy-
matic mutant toxin has no negative effects on rate of gain (11)
(model A of this study), which is in sharp contrast to the
negative effects observed with a toxoid induced by exposure of
SLT-IIe to formaldehyde (11).
Serum antibody titers to SLT-IIe induced by vaccination
with SLT-IIe(E167Q) varied in the three models in the present
study, and these titers were lower than titers obtained in a
previous study (11). The vaccination protocols in the three
models of the present study and in the previous study were
identical. Different genetic backgrounds, nutrition, or other
factors may have accounted for these variations in serum an-
tibody titers. An unexpected observation with vaccinated con-
trols in models A and C of the present study was the increase
in serum anti-SLT-IIe titers after oral challenge. The reason
for this increase after oral challenge with the nontoxigenic
strain 123 is unknown and was not investigated. Possibly, ex-
posure of pigs to bacterial lipopolysaccharide caused a gener-
alized stimulation of the immune system which increased se-
rum antibody titers in these two models.
The protein contents of diets in models A and B were similar
(17 to 18%), while the diet in model C had a higher protein
content (21%). Identical inoculation methods were used in
models B and C. The feeds in models B and C were similar
with regard to nonprotein factors: energy content (3,200 to
3,300 kcal [ca. 13,400 to 13,800 kJ]/kg), crude fiber content
(3%), and fat content (6%). The protein content in feeds in
these two models was modified by changing the ratio of soy-
bean meal to ground corn. Host genetic factors play a role in
susceptibility to edema disease (5) and could have accounted
for the differences in susceptibility in the various models de-
scribed herein. However, all pigs in models B and C were
derived from the same breeding herd and all of these pigs were
determined to be genetically susceptible to edema disease on
the basis of an in vitro adhesion assay (data not shown) (6).
Therefore, diet, not genetics, was likely responsible for the
differences in susceptibility to edema disease in models B and
C, and this study provides further evidence of the role of diet
in susceptibility to edema disease (4, 36).
The data from model C demonstrate that clinical edema
disease has a negative effect on both rate of gain and ratio of
average daily feed consumption/weight gain. These reductions
may be due to direct actions of SLT-IIe, as vaccination with
SLT-IIe(E167Q) prevented both the changes in ratio of aver-
age daily feed consumption/weight gain and rate of gain. Al-
though no significant differences between treatment groups
were observed with respect to rates of gain in models A and B,
the rate of gain in nonvaccinated principals was slightly lower
than it was for the other experimental groups. The reason for
the lack of significant differences in models A and B may be
because not all nonvaccinated principals developed vascular
necrosis. A decreased rate of gain was observed previously with
model A when a majority of the pigs had evidence of vascular
necrosis (21). Awad-Masalmeh et al. (1, 2) also observed that
pigs which had been inoculated with SLT-IIe-producing E. coli
had lower rates of gain than pigs experimentally inoculated
with SLT-IIe-producing E. coli after vaccination. Furthermore,
weight gain was reduced in earlier experiments in which pigs
were vaccinated with a formalized (partially inactivated) SLT-
IIe toxoid (11). Therefore, even mild exposures to SLT-IIe
may impact negatively on the rate of gain.
Diarrhea was a common finding with pigs inoculated with
strain S1191 in models B and C. The cause of the diarrhea was
not determined; however, it was probably caused by strain
S1191, as the pigs inoculated with the nonpathogenic E. coli
strain, 123, did not develop diarrhea. Strain S1191 produces
FIG. 2. Effect of vaccination with SLT-IIe(E167Q) and subclinical edema disease on rate of gain in pigs fed a 17% protein diet and inoculated four times. Pigs were
either vaccinated with 50 mg of mutant toxin or not vaccinated at 1 and 2 weeks of age. Vaccinated (n5 11) and nonvaccinated (n5 12) principals were orally inoculated
at 4, 6, 8, and 10 days postweaning with 1010 CFU of strain S1191, and controls (n 5 11) were similarly inoculated with strain 123. S.E., standard error.
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the enterotoxin STb, which would not have been neutralized by
antibodies generated by vaccination with SLT-IIe(E167Q).
This study demonstrated that a nontoxic, genetically modi-
fied SLT-IIe induced antitoxic immunity that protected pigs
against experimental challenge with an SLT-IIe-producing
strain of E. coli. More importantly, it establishes the potential
for using genetically modified, nontoxic Shiga-like toxins for
prevention of disease caused by Shiga-like-toxin-producing E.
coli in other species, such as hemolytic-uremic syndrome in
humans.
ACKNOWLEDGMENTS
We thank Bob Morgan, Norm Lyon, and Rob Schneider for their
assistance in the animal experiments and Annette Bates for manuscript
preparation.
REFERENCES
1. Awad-Masalmeh, M., H. Reitinger, and H. Willinger. 1988. Efficacy of
edema principle toxin as a vaccine against edema disease of weaned piglets,
p. 116. In Proceedings of the 10th International Pig Veterinary Society
Congress, Rio de Janeiro, Brazil.
2. Awad-Masalmeh, M., M. Schuh, J. Kofer, and E. Quakyl. 1989. Uberprufung
der Schutzwirkung eines Toxoidimpfstoffes gegen die Odemkrankheit des
Absetzferkels im Infektionsmodel. Dtsch. Tieraerztl. Wochenschr. 96:419–
421.
3. Bertschinger, H. U., M. Bachmann, C. Mettler, A. Pospischil, E. M.
Schraner, M. Stamm, T. Sydler, and P. Wild. 1990. Adhesive fimbriae pro-
duced in vivo by Escherichia coli O139:K12(B):H1 associated with entero-
toxaemia in pigs. Vet. Microbiol. 25:267–281.
4. Bertschinger, H. U., E. Eggenberger, H. Jucker, and H. P. Pfirter. 1979.
Evaluation of low nutrient, high fiber diets for the prevention of porcine
Escherichia coli enterotoxaemia. Vet. Microbiol. 3:281–290.
5. Bertschinger, H. U., M. Stamm, and P. Vogeli. 1993. Inheritance of resis-
tance to oedema disease in the pig: experiments with Escherichia coli-ex-
pressing fimbriae 107. Vet. Microbiol. 35:79–89.
6. Bosworth, B. T., R. A. Green, and B. A. Morrison. 1994. Edema disease: a
search for a genetic link. J. Am. Assoc. Swine Pract. 2:19–23.
7. Chanter, N., G. A. Hall, A. P. Bland, A. J. Hayle, and K. R. Parsons. 1986.
Dysentery in calves caused by an atypical strain of Escherichia coli (S102-9).
Vet. Microbiol. 12:241–253.
8. Dobrescu, L. 1983. New biological effect of edema disease principle (Esch-
erichia coli neurotoxin) and its use as an in vitro assay for this toxin. Am. J.
Vet. Res. 44:31–34.
9. Endo, Y., K. Tsurugi, T. Yutsudo, Y. Takeda, K. Ogasawara, and K. Iga-
rashi. 1988. Site of action of a verotoxin (VT2) from Escherichia coli
O157:H7 and Shiga toxin on eukaryotic ribosomes. Eur. J. Biochem. 171:
45–50.
10. Gannon, V. P. J., C. L. Gyles, and B. P. Wilcock. 1989. Effects of Escherichia
coli Shiga-like toxins (verotoxins) in pigs. Can. J. Vet. Res. 53:306–312.
11. Gordon, V. M., S. C. Whipp, H. W. Moon, A. D. O’Brien, and J. E. Samuel.
1992. An enzymatic mutant of Shiga-like toxin type II variant is a vaccine
candidate for edema disease of swine. Infect. Immun. 60:485–502.
12. Hovde, C. J., S. B. Calderwood, J. J. Mekalanos, and R. J. Collier. 1988.
Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin
I. Proc. Natl. Acad. Sci. USA 85:2568–2572.
13. Howard, J. G. 1955. Observations on the intoxication produced in mice and
rabbits by the neurotoxin of Shigella shigae. Br. J. Exp. Pathol. 36:439–446.
14. Igarashi, K., T. K. Ogasawara, K. Ito, T. Yutsudo, and Y. Takeda. 1987.
Inhibition of elongation factor-1 dependent aminoacyl-tRNA binding to
ribosomes by Shiga-like toxin I (VT1) from Escherichia coli O157:H7 and by
Shiga toxin. FEMS Microbiol. Lett. 44:91–94.
15. Imberechts, H., H. DeGreve, J.-P. Hernalsteens, C. Schlicker, H. Bouchet, P.
Pohl, G. Charlier, H. U. Bertschinger, P. Wild, J. Vandekerckhove, J. Van
Damme, M. Van Montagu, and P. Lintermans. 1993. The role of adhesive
F107 fimbriae and of SLT-IIe toxin in the pathogenesis of edema disease in
pigs. Zentralbl. Bakteriol. 278:445–450.
16. Islam, M. S., and W. H. Stimson. 1990. Production and characterization of
monoclonal antibodies with therapeutic potential against Shiga toxin. J. Clin.
Lab. Immunol. 33:11–16.
17. Johnson, W. M., H. Lior, and G. S. Bezanson. 1983. Cytotoxic Escherichia
coli O157:H7 associated with haemorrhagic colitis in Canada. Lancet i:76.
(Letter.)
18. Karmali, M. A., M. Petric, C. Lim, P. C. Fleming, G. S. Arbus, and H. Lior.
1985. The association between idiopathic hemolytic uremic syndrome and
infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 151:775–782.
19. Karmali, M. A., M. Petric, C. Lim, P. C. Fleming, and B. T. Steele. 1983.
FIG. 3. Effect of vaccination with SLT-IIe(E167Q) and clinical edema disease on rate of gain in pigs fed a 21% protein diet and inoculated four times. Pigs were
either vaccinated with 50 mg of mutant toxin or not vaccinated at 1 and 2 weeks of age. Vaccinated (n5 8) and nonvaccinated (n5 11) principals were orally inoculated
at 4, 6, 8, and 10 days postweaning with 1010 CFU of strain S1191, and controls (n 5 11) were similarly inoculated with strain 123. S.E., standard error.
VOL. 64, 1996 EDEMA DISEASE VACCINE 59
 o
n
 Septem
ber 21, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
Escherichia coli cytotoxin, hemolytic-uraemic syndrome and hemorrhagic
colitis. Lancet i:1299–1300. (Letter.)
20. Karmali, M. A., M. Petric, B. T. Steele, and C. Lim. 1983. Sporadic cases of
hemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-
producing Escherichia coli in stools. Lancet i:619–620. (Letter.)
21. Kausche, F. M. 1989. M.S. thesis. Iowa State University, Ames.
22. Kausche, F. M., E. A. Dean, L. H. Arp, J. E. Samuel, and H. W. Moon. 1992.
An experimental model for edema disease (Escherichia coli enterotoxemia)
in pigs: subclinical disease manifest as vascular necrosis. Am. J. Vet. Res.
53:281–287.
23. Kurtz, H. J., M. E. Bergeland, and D. M. Barnes. 1969. Pathologic changes
in edema disease of swine. Am. J. Vet. Res. 30:791–806.
24. MacLeod, D. L., and D. L. Gyles. 1991. Immunization of pigs with a purified
Shiga-like toxin II variant toxoid. Vet. Microbiol. 29:309–318.
25. Mainil, J. G., C. J. Duchesnes, S. C. Whipp, L. R. M. Marques, A. D.
O’Brien, T. A. Casey, and H. W. Moon. 1987. Shiga-like toxin production and
attaching effacing activity of Escherichia coli associated with calf diarrhea.
Am. J. Vet. Res. 48:743–748.
26. Marques, L. R. M., J. S. M. Peiris, S. J. Cryz, and A. D. O’Brien. 1987.
Escherichia coli strains isolated from pigs with edema disease produce a
variant of Shiga-like toxin II. FEMS Microbiol. Lett. 44:33–38.
27. Neilsen, N. O. 1986. Edema disease, p. 528–540. In A. D. Leman, B. Straw,
R. D. Glock, et al. (ed.), Diseases of swine, 6th ed. Iowa State University
Press, Ames.
28. O’Brien, A. D., and R. K. Holmes. 1987. Shiga and Shiga-like toxins. Micro-
biol. Rev. 51:206–220.
29. O’Brien, A. D., T. A. Lively, M. E. Chen, S. W. Rothman, and S. B. Formal.
1983. E. coli O157:H7 strains associated with haemorrhagic colitis in the
United States produce a S. dysenteriae 1 (Shiga)-like cytotoxin. Lancet i:702.
(Letter.)
30. Ogasawara, T., K. Ito, K. Igarsha, T. Yutsudo, N. Nakabayashi, and Y.
Takeda. 1988. Inhibition of protein synthesis by a Vero toxin (VT2 or
Shiga-like toxin II) produced by Escherichia coli O157:H7 at the level of
elongation factor 1-dependent aminoacyl-tRNA binding to ribosomes. Mi-
crob. Pathog. 4:127–135.
31. Samuel, J. E., L. P. Perera, S. Ward, A. D. O’Brien, V. Ginsburg, and H. C.
Krivan. 1990. Comparison of the glycolipid receptor specificities of Shiga-
like toxin type II and Shiga-like toxin type II variants. Infect. Immun. 58:
611–618.
32. SAS Institute, Inc. 1987. SAS user’s guide: statistics, 6th ed. SAS Institute,
Inc., Cary, N.C.
33. Scotland, S. M., B. Rowe, H. R. Smith, G. A. Willshaw, and R. J. Gross. 1988.
Vero cytotoxin-producing strains of E. coli from children with hemolytic
uraemic syndrome and their detection by specific DNA probes. J. Med.
Microbiol. 25:237–243.
34. Sherwood, D., D. R. Snodgrass, and A. D. O’Brien. 1985. Shiga-like toxin
production from Escherichia coli associated with calf diarrhoea. Vet. Rec.
116:217–218.
35. Smith, H. W., P. Green, and Z. Parsell. 1983. Vero cell toxins in Escherichia
coli and related bacteria: transfer by phage and conjugation and toxic action
in laboratory animals, chickens and pigs. J. Gen. Microbiol. 129:3121–3137.
36. Smith, H. W., and S. Halls. 1968. The production of oedema disease and
diarrhoea in weaned pigs by the oral administration of Escherichia coli:
factors that influence the course of the experimental disease. J. Med. Mi-
crobiol. 1:45–59.
37. Timoney, J. F. 1950. Oedema disease of swine. Vet. Rec. 62:748–758.
38. Wadolkowski, E. A., L. M. Sung, J. A. Burris, J. E. Samuel, and A. D.
O’Brien. 1990. Acute renal tubular necrosis and death of mice orally infected
with Escherichia coli strains that produce Shiga-like toxin type II. Infect.
Immun. 58:3959–3965.
Editor: P. E. Orndorff
60 BOSWORTH ET AL. INFECT. IMMUN.
 o
n
 Septem
ber 21, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
